Enovis Corporation FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual Form 10-K, not a standalone fourth-quarter report; separate Q4 results are not clearly provided. Enovis is a medical technology company operating through Prevention & Recovery and Reconstructive segments. Fiscal 2023 was the first full year following the 2022 separation of ESAB.
Business context
- Prevention & Recovery: Orthopedic bracing, recovery sciences, vascular therapy, compression, pain management, physical therapy and related products.
- Reconstructive: Hip, knee, shoulder, elbow, foot, ankle and finger implants, surgical instruments and surgical productivity technologies.
- Approximately 32% of 2023 sales originated outside the United States, primarily in Europe. The company employed approximately 6,550 people at year-end.
- Enovis completed the Novastep acquisition, the D.N.E./SEAL asset acquisition and the Precision AI asset acquisition in 2023.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales | $1,707.2 million | $1,563.1 million | +9.2% |
| Gross profit | $990.8 million | $869.4 million | +14.0% |
| Gross margin | 58.0% | 55.6% | +240 bps |
| Operating loss | $(65.7) million | $(71.2) million | Improved by $5.5 million |
| Operating margin | (3.8)% | (4.6)% | +80 bps |
| Net loss from continuing operations | $(53.8) million | $(38.2) million | Loss increased $15.6 million |
| Adjusted EBITDA | $269.2 million | $236.1 million | +14.0% |
| Adjusted EBITDA margin | 15.8% | 15.1% | +70 bps |
| Net cash from operating activities | $135.0 million | $(55.9) million | Improved by $190.8 million |
Segment performance
| Segment | 2023 sales | Sales change | 2023 Adjusted EBITDA | Margin |
|---|---|---|---|---|
| Prevention & Recovery | $1,076.8 million | +4.8% | $152.5 million | 14.2% |
| Reconstructive | $630.4 million | +17.7% | $116.7 million | 18.5% |
Growth was driven by higher volumes, market outperformance, new product launches and pricing actions. Reconstructive sales increased particularly strongly, while acquisitions and related integration costs remained dilutive to reported margins but management expects future accretion.
Liquidity, cash flow and debt
- Cash and cash equivalents were $36.2 million at December 31, 2023; cash, cash equivalents and restricted cash totaled $44.8 million.
- Investing cash use was $242.5 million, including $152.8 million for acquisitions and investments and $122.2 million for property, plant, equipment and intangibles, partially offset by $32.6 million of asset-sale proceeds.
- Net financing cash inflow was $127.8 million, principally reflecting debt borrowings, including the $460.0 million convertible-note issuance, partially offset by debt repayments, issuance costs and the $62.0 million capped-call payment.
- Debt consisted primarily of $460.0 million principal amount of 3.875% senior unsecured convertible notes due 2028 and $20.0 million drawn under the revolving facility; carrying-value debt was $466.2 million.
- The $900.0 million revolving facility had approximately $880.0 million of availability at year-end. The weighted-average interest rate on Credit Agreement borrowings was 6.58%.
- Management stated that liquidity is adequate for operations for the next twelve months and the foreseeable future. The company was in compliance with its debt covenants at year-end.
Material changes versus the prior comparable period
- Sales, gross profit and Adjusted EBITDA increased, with gross margin expanding 240 basis points and Adjusted EBITDA margin expanding 70 basis points.
- GAAP continuing-operations net loss increased despite improved operating loss because 2022 included substantial one-time gains, including a $102.7 million gain on the ESAB investment, an $8.8 million gain on a cost-basis investment and a $36.7 million insurance settlement gain.
- Operating expenses increased, including selling, general and administrative expense of $830.3 million, research and development expense of $75.3 million, medical-device-regulation costs of $27.4 million and strategic transaction costs of $38.3 million.
- Operating cash flow improved substantially from an outflow in 2022, although working capital remained a use of cash, particularly because of higher inventories and business growth.
- Goodwill increased to $2.06 billion. Quantitative impairment testing identified no impairment, but excess fair value over carrying value was relatively narrow at approximately 4% for Prevention & Recovery and 8% for Reconstructive.
Outlook, commentary, risks and unusual items
- The company emphasizes organic growth, continuous improvement through its EGX operating system, acquisitions and expansion of higher-growth Reconstructive offerings.
- On January 3, 2024, Enovis completed the LimaCorporate acquisition at an enterprise value of approximately €800 million, funded through approximately €700 million of cash consideration, equity consideration of approximately €100 million and a new $400 million term-loan facility. Lima results are not included in 2023 results.
- The Lima transaction increases leverage, international exposure, integration requirements and potential share dilution. Approximately 1.94 million Enovis shares are expected to be issued to the seller, subject to contractual conditions and adjustments.
- Inflation in raw materials, labor, energy and logistics remains a margin risk. Management has used pricing actions, particularly in Prevention & Recovery, to offset cost pressure.
- Medical-device regulation, including EU MDR and UK certification requirements, reimbursement reductions, product liability, recalls, clinical and regulatory approvals, healthcare fraud-and-abuse laws, privacy and cybersecurity requirements are significant ongoing risks.
- Foreign-exchange exposure is material. A hypothetical 10% depreciation in major currencies against the U.S. dollar would reduce equity by approximately $110 million, according to the filing.
- Pending legal proceedings are described as ordinary-course matters that management does not expect to have a material adverse effect, although outcomes cannot be assured. Purchase obligations were $145.9 million, letters of credit and surety bonds were $11.5 million, and pension contributions expected in 2024 were $3.5 million.
- The filing provides no explicit quantitative 2024 revenue or earnings guidance.
Important facts for investors to verify
- Reconcile the annual results with the separate fourth-quarter filing or earnings release because this Form 10-K does not provide a clear standalone Q4 income statement.
- Assess the post-Lima capital structure, including the $400 million term loan, convertible-note dilution, covenant headroom and integration costs.
- Evaluate whether Reconstructive growth and expected acquisition synergies offset higher amortization, MDR costs, strategic transaction costs and restructuring charges.
- Monitor goodwill sensitivity, particularly the narrow valuation cushions disclosed for both reporting units.
- Review EU MDR and UK certification progress, reimbursement trends, product-liability exposure and any recall or regulatory developments.
- Track operating cash conversion, inventory levels, acquisition spending and the company’s ability to fund growth while maintaining liquidity.
- Review the treatment and timing of unusual items, including the Lima-related foreign-currency hedge, discontinued-operation gains and contingent consideration obligations.